https://www.bioworld.com/rss en-us City Therapeutics Inc. has completed a $99.5 million series B financing to support its pipeline of RNA interference (RNAi) therapeutics and accelerate its next-generation RNAi engineering platform. http://www.bioworld.com/articles/731762 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731762-city-therapeutics-advances-rnai-pipeline-with-series-b-financing Antibody-drug conjugate (ADC) specialist Ona Therapeutics SL has closed an oversubscribed series B at $86.6 million, as clinical development of the lead program ONA-255 in advanced treatment-resistant breast cancer gathers steam. http://www.bioworld.com/articles/731620 Thu, 04 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731620-ona-raises-866m-series-b-for-adcs-to-treat-advanced-cancers 3D dollar sign Create Medicines Inc. closed a $122 million series B financing round to support its pipeline of therapies that use mRNAs delivered via liquid nanoparticles to express chimeric antigen receptors (CARs) in T cells, NK cells and myeloid cells inside the body of patients. The Cambridge, Mass.-based company estimates the capital will last through 2028, providing the opportunity for multiple clinical readouts of its various products. http://www.bioworld.com/articles/731326 Tue, 19 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731326-create-medicines-secures-122m-for-in-vivo-cars Black dollar sign on ombre blue background Create Medicines Inc. has closed a $122 million series B funding round to support progression of its pipeline of in vivo CAR therapies across autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform directly engineers T cells, NK cells and myeloid cells inside the body to enable scalable, repeat-dose, off-the-shelf immunotherapies. http://www.bioworld.com/articles/731122 Fri, 15 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731122-financing-at-create-medicines-to-advance-in-vivo-car-therapies Dollar sign dropper and test tube Nvision Imaging Technologies GmbH raised $55 million in a series B financing round led by Abbott Laboratories for its quantum-enhanced sensing platform, Polaris, which uses quantum technology to boost the MRI signal of sugar-based imaging agents to enable real-time measurement of metabolism on standard MRI systems. Sella Brosh, CEO and co-founder of Nvision, told BioWorld that the funds are extremely important as the company is scaling the Polaris systems to many more sites worldwide, which is a capital intensive process. BioWorld that the funds are extremely important as the company is scaling the Polaris systems to many more sites worldwide, which is a capital intensive process.]]> http://www.bioworld.com/articles/731059 Wed, 13 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731059-nvision-secures-55-million-with-backing-from-abbott Nvision's Polaris system Polaris quantum-enhanced sensing platform. Credit: Nvision Imaging Technologies GmbH Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development. http://www.bioworld.com/articles/730420 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730420-new-china-biotech-syneron-chases-macrocycle-frontier Multicolor peptide illustration Tr1x Inc. was founded with a simple but ambitious goal: to change how autoimmune and inflammatory diseases are treated, moving away from chronic treatment and toward durable cures. “We are trying to flip the script on regulatory T cells (Tregs),” Tr1x CEO David de Vries told BioWorld. “The goal is to reset the immune system rather than continuously suppress it, and we believe we have a unique technology to do that.” BioWorld. “The goal is to reset the immune system rather than continuously suppress it, and we believe we have a unique technology to do that.”]]> http://www.bioworld.com/articles/730296 Tue, 14 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730296-immune-reset-is-ambition-of-tr1xs-allogenic-tr1-cell-therapy Cell therapy illustration Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. http://www.bioworld.com/articles/730275 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730275-sidewinders-bispecific-adc-approach-draws-137m-series-b Blue digital dollar sign Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development. http://www.bioworld.com/articles/730152 Wed, 08 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730152-new-china-biotech-syneron-chases-macrocycle-frontier Multicolor peptide illustration Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. http://www.bioworld.com/articles/730148 Wed, 08 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730148-sidewinders-bispecific-adc-approach-draws-137m-series-b Blue digital dollar sign Ambrosia Biosciences Inc., named after the drink of the Greek gods, secured a $100 million series B to advance its preclinical pipeline of oral obesity drugs. The startup formed after Pfizer Inc. shuttered its Boulder, Colo.-based research facility that the pharma gained through its 2019 acquisition of Array Biopharma Inc. http://www.bioworld.com/articles/730076 Thu, 02 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline Pills, bottle, scale and-measuring tape Ambrosia Biosciences Inc. has announced a $100 million oversubscribed series B financing intended to support progression of the company’s oral small-molecule GLP-1 candidate and other novel cardiometabolic programs into clinical development. http://www.bioworld.com/articles/730060 Wed, 01 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730060-series-b-financing-supports-ambrosias-cardiometabolic-pipeline Blue digital dollar sign Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. http://www.bioworld.com/articles/730034 Fri, 27 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/730034-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs Hand holding dollar sign Pinnacle Medicines Inc. secured $89 million in a series B financing, bringing the total raised by the company to $134 million. The round was co-led by LAV and Foresite Capital. http://www.bioworld.com/articles/729903 Thu, 26 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729903-pinnacle-raises-an-89m-series-b-for-its-oral-peptide-programs Hand holding dollar sign Crossbow Therapeutics Inc. closed a $77 million series B round to support an ongoing phase I Crosscheck-001 trial of lead program, CBX-250, and additional T-Bolt immunotherapies targeting a broad range of cancers. http://www.bioworld.com/articles/729747 Thu, 19 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729747-crossbow-raises-77m-series-b-for-t-cell-mimicking-antibodies Antibodies illustration Breezebio Inc., formerly known as Genedit Inc., has closed $60 million in series B financing to advance its first internal therapeutic programs toward the clinic and to continue expansion of the company’s Nanogalaxy delivery platform. http://www.bioworld.com/articles/729055 Thu, 26 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729055-genedit-changes-name-closes-series-b-for-new-therapeutic-programs 3D dollar sign After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor. http://www.bioworld.com/articles/729231 Tue, 24 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/729231-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor. http://www.bioworld.com/articles/728990 Fri, 13 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728990-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) After closing an oversubscribed $85 million series B round, Quantx Biosciences Inc. is gearing up to begin clinical trials of its two lead immunology compounds, a STAT6 oral small-molecule inhibitor and an IL-17 oral small-molecule inhibitor. http://www.bioworld.com/articles/728848 Thu, 12 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728848-quantx-raises-85m-to-advance-oral-immunology-drugs Interleukin 17 (IL-17) Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering. http://www.bioworld.com/articles/728806 Tue, 10 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728806-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering. http://www.bioworld.com/articles/728800 Tue, 10 Feb 2026 09:00:00 -0500 https://www.bioworld.com/articles/728800-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering. http://www.bioworld.com/articles/728701 Mon, 09 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728701-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d Park Tae-yong, vice president and cofounder, Galux Park Tae-yong, vice president and cofounder, Galux Inc. Lixa Pty Ltd. has formed a partnership with the Global Antibiotic Research & Development Partnership and announced a AU$28 million (US$20 million) series B round to take Neox-121 to the clinic to fight antimicrobial resistance. http://www.bioworld.com/articles/728547 Tue, 03 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728547-switching-off-resistance-lixas-bold-amr-bet Maud Eijkenboom, CEO, Lixa Pty Ltd. Maud Eijkenboom, CEO, Lixa Pty Ltd. Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did not disclose specifics around the licensed candidate, except that it was derived from its LEAD (Ligand and Enhancer Assisted Delivery) platform. http://www.bioworld.com/articles/728517 Tue, 03 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728517-genentech-licenses-sanegenes-rnai-asset-in-17b-deal Interfering RNA (RNAi) Neuropsychiatry specialist, Exciva GmbH raised €51 million (US$59.9 million) in a series B round to fund a phase II/III trial of Deraphan, a combination therapy for treating agitation in patients with Alzheimer’s disease. http://www.bioworld.com/articles/728132 Tue, 20 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/728132-exciva-adds-599m-series-b-for-alzheimers-disease-agitation-trial White Euro symbol on blue background Mediar Therapeutics Inc. has announced an oversubscribed $76 million series B financing to support its novel anti-fibrotics through clinical studies. The funding will also be used to advance MTX-439 into phase I for the treatment of chronic kidney disease (CKD)-associated fibrosis. http://www.bioworld.com/articles/727743 Thu, 08 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727743-series-b-financing-at-mediar-therapeutics Doctor with illustration of kidneys Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had planned to take some time off to rest and do a little traveling, but then the pandemic hit. “This was a great time [to start a new company],” Cui told BioWorld. “Nothing to do but reading and thinking.” BioWorld. “Nothing to do but reading and thinking.”]]> http://www.bioworld.com/articles/727531 Wed, 31 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727531-blossomhill-advancing-egfr-clk-inhibitors-with-series-b-extension Blue dollar sign on white background Vyriad Inc. has announced the closing of a $25 million final tranche to its series B financing, bringing the total series B round to $85 million. This additional funding will support first-in-human testing of VV-169, Vyriad’s in vivo CAR T candidate, in patients with relapsed or treatment-refractory multiple myeloma. http://www.bioworld.com/articles/727442 Wed, 24 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727442-further-financing-at-vyriad-to-advance-vv-169-into-clinic Dollar sign droplet above test tube Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital alchemy,’” Kim told BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces. BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]> http://www.bioworld.com/articles/727277 Wed, 17 Dec 2025 09:00:00 -0500 https://www.bioworld.com/articles/727277-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery Kim Woo-youn, CEO and cofounder, Hits Kim Woo-youn, CEO and cofounder, Hits Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital alchemy,’” Kim told BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces. BioWorld, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]> http://www.bioworld.com/articles/727003 Tue, 16 Dec 2025 12:00:00 -0500 https://www.bioworld.com/articles/727003-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery Kim Woo-youn, CEO and cofounder, Hits Kim Woo-youn, CEO and cofounder, Hits